These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34799554)

  • 1. TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer.
    Wen YC; Liu YN; Yeh HL; Chen WH; Jiang KC; Lin SR; Huang J; Hsiao M; Chen WY
    Oncogenesis; 2021 Nov; 10(11):81. PubMed ID: 34799554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
    Chen WY; Thuy Dung PV; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Hsiao M; Huang J; Wen YC; Liu YN
    Redox Biol; 2023 Jun; 62():102686. PubMed ID: 36963289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of TGF-β - SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK.
    Natani S; Sruthi KK; Asha SM; Khilar P; Lakshmi PSV; Ummanni R
    Cell Signal; 2022 Mar; 91():110240. PubMed ID: 34986386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.
    Enriquez C; Cancila V; Ferri R; Sulsenti R; Fischetti I; Milani M; Ostano P; Gregnanin I; Mello-Grand M; Berrino E; Bregni M; Renne G; Tripodo C; Colombo MP; Jachetti E
    Cancer Res; 2021 Aug; 81(16):4257-4274. PubMed ID: 34185677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular aspects of prostate cancer with neuroendocrine differentiation.
    Li Q; Zhang CS; Zhang Y
    Chin J Cancer Res; 2016 Feb; 28(1):122-9. PubMed ID: 27041934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive role of BDNF in therapy-induced neuroendocrine prostate cancer.
    Liu YN; Chen WY; Liu MK; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Wang WH; Abou-Kheir W; Wen YC
    Mol Oncol; 2024 Jun; 18(6):1665-1686. PubMed ID: 38381121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.
    Lin LC; Gao AC; Lai CH; Hsieh JT; Lin H
    Cancer Lett; 2017 Apr; 391():74-82. PubMed ID: 28109910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review.
    Usmani S; Orevi M; Stefanelli A; Zaniboni A; Gofrit ON; Bnà C; Illuminati S; Lojacono G; Noventa S; Savelli G
    Crit Rev Oncol Hematol; 2019 Jun; 138():29-37. PubMed ID: 31092382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
    Wang C; Peng G; Huang H; Liu F; Kong DP; Dong KQ; Dai LH; Zhou Z; Wang KJ; Yang J; Cheng YQ; Gao X; Qu M; Wang HR; Zhu F; Tian QQ; Liu D; Cao L; Cui XG; Xu CL; Xu DF; Sun YH
    Clin Cancer Res; 2018 Feb; 24(3):708-723. PubMed ID: 29191973
    [No Abstract]   [Full Text] [Related]  

  • 10. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
    Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
    Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation.
    Asberry AM; Liu S; Nam HS; Deng X; Wan J; Hu CD
    Comput Struct Biotechnol J; 2022; 20():5873-5885. PubMed ID: 36382181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients.
    Komiya A; Yasuda K; Watanabe A; Fujiuchi Y; Tsuzuki T; Fuse H
    Mol Clin Oncol; 2013 Mar; 1(2):257-262. PubMed ID: 24649157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-1205 Regulation of FRYL in Prostate Cancer.
    Naidoo M; Levine F; Gillot T; Orunmuyi AT; Olapade-Olaopa EO; Ali T; Krampis K; Pan C; Dorsaint P; Sboner A; Ogunwobi OO
    Front Cell Dev Biol; 2021; 9():647485. PubMed ID: 34386489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells.
    Chang PC; Wang TY; Chang YT; Chu CY; Lee CL; Hsu HW; Zhou TA; Wu Z; Kim RH; Desai SJ; Liu S; Kung HJ
    PLoS One; 2014; 9(2):e88556. PubMed ID: 24551118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells.
    Natani S; Dhople VM; Parveen A; Sruthi KK; Khilar P; Bhukya S; Ummanni R
    Biochim Biophys Acta Mol Cell Res; 2021 Sep; 1868(10):119085. PubMed ID: 34171447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
    Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 Loop.
    Lee GT; Kwon SJ; Lee JH; Jeon SS; Jang KT; Choi HY; Lee HM; Kim WJ; Lee DH; Kim IY
    Prostate; 2011 Oct; 71(14):1525-37. PubMed ID: 21374653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
    Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
    Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of EHF facilitates the development of treatment-induced neuroendocrine prostate cancer.
    Long Z; Deng L; Li C; He Q; He Y; Hu X; Cai Y; Gan Y
    Cell Death Dis; 2021 Jan; 12(1):46. PubMed ID: 33414441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells.
    Uysal-Onganer P; Kawano Y; Caro M; Walker MM; Diez S; Darrington RS; Waxman J; Kypta RM
    Mol Cancer; 2010 Mar; 9():55. PubMed ID: 20219091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.